{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'potentially contaminated food, close contact with carriers and vectors). Subsequent medical', 'assessments (eg, stool exam, blood tests) must be performed in order to rule out parasitic', 'infection/infestation (see also Section 10.4.1.3).', '10.6.4 Elevated Liver Function Tests', 'No preclinical and clinical data has suggested any hepatic toxicity of dupilumab; however, as a', 'general consideration of clinical development, the administration of immunosuppressant or', 'immunomodulating agents may represent an additional risk factor for hepatotoxicity.', 'Hepatitis virus tests and liver function tests (LFT), will be performed at Screening Visit 1, prior to', 'randomization to exclude those patients with high risk of hepatitis infection or severe liver injury', 'from this study (see Section 7.2.3).', 'In order to closely follow potential liver abnormalities, assessment of total protein, albumin, total', 'bilirubin, ALT, AST, and ALP are measured as part of the clinical laboratory testing.', 'Clinical laboratory testing at Screening Visit 1 adds hepatitis screen (HBs-Ag, HBs-Ab, IgM and', 'total-HBc-Ab, and HVC-Ab).', 'Guidance for the investigation of elevated LFTs is provided in Appendix K.', '10.7 ADVERSE EVENTS MONITORING', 'All events will be managed and reported in compliance with all applicable regulations, and', 'included in the final clinical study report.', 'Property of the Sanofi Group - strictly confidential', 'Page 108', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '11', 'STATISTICAL CONSIDERATIONS', '11.1 DETERMINATION OF SAMPLE SIZE', 'The sample size of this study was based on a comparison between dupilumab versus placebo with', 'regard to the primary endpoint of annualized rate of severe exacerbations over 52 weeks of', 'treatment for the 3 populations of interest: patients with baseline blood eosinophils 300 cells/L,', 'patients with baseline blood eosinophils >150 cells/L, and patients with type 2 inflammatory', 'phenotype (baseline blood eosinophils >150 cells/L or baseline FeNO >20 ppb), with assuming', 'the number of severe exacerbations follows a negative binomial distribution and a randomization', 'ratio of 2:1.', 'The sample size calculation assumes a linear discontinuation rate (20% at 1 year), thus the', 'average exposure duration for patients is 0.9 year. The assumed relative risk reductions are based', 'on the results in the phase 3 asthma study EFC13579 (QUEST).', 'To achieve target sample size for each of the populations stated above, approximately 402 patients', 'in the overall population (268 for dupilumab and 134 for placebo) need to be randomized', 'assuming approximately 86% of the randomized patients have type 2 inflammatory phenotype', '(baseline blood eosinophils >150 cells/L or baseline FeNO >20 ppb), approximately 81% of the', 'randomized patients have baseline blood eosinophils >150 cells/L, and approximately 64% of', 'the randomized patients have baseline blood eosinophils >300 cells/uL.', 'Patients will be randomized (2:1 ratio) to receive dupilumab or matching placebo. After a patient', 'is randomly assigned to dupilumab or matching placebo, the dosage of dupilumab or matching', 'placebo for the patient, 200 or 100 mg SC once q2w, will be determined based on baseline body', 'weight >30 kg or 30 kg, respectively.', 'Property of the Sanofi Group - strictly confidential', 'Page 109', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Randomization will be stratified by ICS dose (medium-dose versus high-dose) and eosinophil', 'count (<300 cells/L versus >300 cells/uL) at Screening, and by region (Latin America:', 'Argentina, Brazil, Colombia, Chile and Mexico; Eastern Europe: Poland, Hungary, Romania,', 'Lithuania, Turkey, Russia and Ukraine; Western Countries: Australia, Canada, Italy, South', 'Africa, Spain, and USA). The final definition of region may be updated in the SAP, if additional', 'countries are included in the study. If during the study, additional countries are included,', 'necessary changes will be made to the randomization algorithm. These changes will be', 'documented in the SAP.', 'Note that if any change is made to the definition of stratum in the future, particularly, the', 'definition of region, the changes in the region definition will be included in SAP and the IVRS', 'will be reconfigured to ensure a correct randomization according to the new definition.', '11.2 DISPOSITION OF PATIENTS', 'Screened patients are defined as any patient who met the inclusion criteria and whose parent(s) or', 'legal guardian signed the pediatric informed consent.', 'Randomized patients consist of all patients with a treatment kit number allocated and recorded in', 'IVRS database, and regardless of whether the treatment kit was used or not.', 'Patients treated without being randomized will not be considered as randomized and will not be', 'included in any efficacy population.', 'The safety experience of patients treated and not randomized will be reported in the safety', 'population according to the actual treatment received.', '11.3 ANALYSIS POPULATIONS', '11.3.1 Efficacy Populations', 'The full intent-to-treat (ITT) population is defined as all randomized patients.', 'Type 2 inflammatory phenotype population is defined as the randomized patients with baseline', 'blood eosinophils > >150 cells/uL or baseline FeNO >20 ppb.', 'Baseline blood eosinophils >300 cells/L population is defined as the randomized patients with', 'baseline blood eosinophils 300 cells/L.', 'Baseline blood eosinophils >150 cells/L population is defined as the randomized patients with', 'baseline blood eosinophils >150 cells/L.', 'All efficacy endpoints will be analyzed based on both the type 2 inflammatory phenotype', 'population and the population with baseline blood eosinophils >300 cells/L.', 'Property of the Sanofi Group - strictly confidential', 'Page 110', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}